US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

Precigen, Inc. - Common Stock (NQ:PGEN)

7.660 -0.150 (-1.92%)
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
News headline image
Precigen: Return On Capital Employed Insights ↗
Precigen (NASDAQ:PGEN) reported Q1 sales of $24.51 million. Earnings fell to a loss of $17.69 million, resulting in a 598.82% decrease from last quarter. In Q4, Precigen earned $3... 
Via Benzinga
News headline image
Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators ↗
Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >